Literature DB >> 17664478

PIEPOC: a new prognostic index for advanced epithelial ovarian cancer--Japan Multinational Trial Organization OC01-01.

Satoshi Teramukai1, Kazunori Ochiai, Harue Tada, Masanori Fukushima.   

Abstract

PURPOSE: The purpose of this study was to construct a simple and powerful prognostic index (PI) of epithelial ovarian cancer, the PIEPOC. PATIENTS AND METHODS: In a retrospective review, data from 768 women with stage III or IV epithelial ovarian cancer from 24 institutions in Japan were evaluated for clinical features predictive of overall survival. A PI and risk groups to predict overall survival after initial surgery were developed using the proportional hazards regression model.
RESULTS: Of six factors, the four prognostic factors that remained independently significant in the analysis of a training sample (538 randomly selected patients) were age, performance status (PS), histologic cell type, and residual tumor size. From the regression function, we derived a PI = 1 (if age 70 and above) + 1 (if PS 1 or 2) + 2 (if PS 3 or 4) + 1 (if mucinous or clear-cell) + 2 (if residual size 0.1 cm and above). Patients were classified into three risk groups (PIEPOC): low risk (PI 0-2), intermediate risk (PI 3), and high risk (PI 4-6). The PIEPOC was equally predictive in a validation sample (n = 230), identifying three groups (5-year survival: 0.67 in low, 0.43 in intermediate, 0.17 in high risk).
CONCLUSION: Our proposed PI, the PIEPOC, was predictive in our patient population and may have utility in clinical practice. Prospective studies would be needed to confirm the prognostic predictive ability of the PIEPOC for patients with advanced epithelial ovarian cancer.

Entities:  

Mesh:

Year:  2007        PMID: 17664478     DOI: 10.1200/JCO.2007.11.0114

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  11 in total

1.  Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy.

Authors:  Tadayuki Kou; Masashi Kanai; Michio Yamamoto; Peng Xue; Yukiko Mori; Yasushi Kudo; Akira Kurita; Norimitsu Uza; Yuzo Kodama; Masanori Asada; Michiya Kawaguchi; Toshihiko Masui; Masaki Mizumoto; Shujiro Yazumi; Shigemi Matsumoto; Kyoichi Takaori; Satoshi Morita; Manabu Muto; Shinji Uemoto; Tsutomu Chiba
Journal:  Int J Clin Oncol       Date:  2015-06-28       Impact factor: 3.402

2.  Incorporation of postoperative CT data into clinical models to predict 5-year overall and recurrence free survival after primary cytoreductive surgery for advanced ovarian cancer.

Authors:  Irene A Burger; Debra A Goldman; Hebert Alberto Vargas; Michael W Kattan; Changhon Yu; Lei Kou; Vaagn Andikyan; Dennis S Chi; Hedvig Hricak; Evis Sala
Journal:  Gynecol Oncol       Date:  2015-06-17       Impact factor: 5.482

3.  Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer: Analysis of the National Cancer Database.

Authors:  J Alejandro Rauh-Hain; Alexander Melamed; Alexi Wright; Allison Gockley; Joel T Clemmer; John O Schorge; Marcela G Del Carmen; Nancy L Keating
Journal:  JAMA Oncol       Date:  2017-01-01       Impact factor: 31.777

4.  Comparison of advanced stage mucinous epithelial ovarian cancer and serous epithelial ovarian cancer with regard to chemosensitivity and survival outcome: a matched case-control study.

Authors:  Emine Karabuk; M Faruk Kose; Deniz Hizli; Salih Taşkin; Burak Karadağ; Taner Turan; Nurettin Boran; Ahmet Ozfuttu; U Fırat Ortaç
Journal:  J Gynecol Oncol       Date:  2013-04-05       Impact factor: 4.401

5.  External validation of three prognostic models for overall survival in patients with advanced-stage epithelial ovarian cancer.

Authors:  R van de Laar; J IntHout; T Van Gorp; S Verdonschot; A M van Altena; C G Gerestein; L F A G Massuger; P L M Zusterzeel; R F P M Kruitwagen
Journal:  Br J Cancer       Date:  2013-11-19       Impact factor: 7.640

6.  Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo Clinic.

Authors:  Andrea E Wahner Hendrickson; Kieran M Hawthorne; Ellen L Goode; Kimberly R Kalli; Krista M Goergen; Jamie N Bakkum-Gamez; William A Cliby; Gary L Keeney; Daniel W Visscher; Yaman Tarabishy; Ann L Oberg; Lynn C Hartmann; Matthew J Maurer
Journal:  Gynecol Oncol       Date:  2015-01-22       Impact factor: 5.482

7.  Metabolic profiling and novel plasma biomarkers for predicting survival in epithelial ovarian cancer.

Authors:  Hongyu Xie; Yan Hou; Jinlong Cheng; Margarita S Openkova; Bairong Xia; Wenjie Wang; Ang Li; Kai Yang; Junnan Li; Huan Xu; Chunyan Yang; Libing Ma; Zhenzi Li; Xin Fan; Kang Li; Ge Lou
Journal:  Oncotarget       Date:  2017-05-09

8.  Prediction of survival outcomes in patients with epithelial ovarian cancer using machine learning methods.

Authors:  E Sun Paik; Jeong Won Lee; Jeong Yeol Park; Ju Hyun Kim; Mijung Kim; Tae Joong Kim; Chel Hun Choi; Byoung Gie Kim; Duk Soo Bae; Sung Wook Seo
Journal:  J Gynecol Oncol       Date:  2019-03-11       Impact factor: 4.401

9.  Determinants of long-term outcome in patients undergoing simultaneous resection of synchronous colorectal liver metastases.

Authors:  Qi Lin; Qinghai Ye; Dexiang Zhu; Ye Wei; Li Ren; Lechi Ye; Qingyang Feng; Pingping Xu; Peng Zheng; Minzhi Lv; Jia Fan; Jianmin Xu
Journal:  PLoS One       Date:  2014-08-27       Impact factor: 3.240

10.  Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer.

Authors:  E Sun Paik; Insuk Sohn; Sun-Young Baek; Minhee Shim; Hyun Jin Choi; Tae-Joong Kim; Chel Hun Choi; Jeong-Won Lee; Byoung-Gie Kim; Yoo-Young Lee; Duk-Soo Bae
Journal:  Cancer Res Treat       Date:  2016-09-27       Impact factor: 4.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.